IMPLANET Reveals Its 2025 Financial Calendar
IMPLANET is a prominent name in the medical technology sector, predominantly focusing on orthopedic solutions. The company has laid out its financial calendar for 2025, detailing critical dates for investors and stakeholders looking to track its performance and strategic direction.
Key Financial Dates for 2025
The financial calendar is pivotal for anyone invested in IMPLANET, as it specifies when the company plans to release various important financial metrics. The timeline includes various revenue announcements that will help investors gauge the company's financial health and trajectory.
Significant Events and Dates
The following are the major financial announcements scheduled for the year:
- 2024 Full-Year Revenue: January 14, 2025
- 2024 Full-Year Results: March 4, 2025
- Annual General Meeting: March 28, 2025
- 2025 First-Quarter Revenue: April 9, 2025
- 2025 First-Half Revenue: July 8, 2025
- 2025 First-Half Results: September 16, 2025
- 2025 Third-Quarter Revenue: October 7, 2025
It’s important to note that these dates are subject to change, and it is advisable to stay tuned for further announcements from the company, particularly after market closures.
About IMPLANET
Founded in 2007, IMPLANET is recognized for its commitment to innovation and quality in manufacturing implants that are pivotal for orthopedic surgery, as well as distributing essential medical equipment. Their offerings particularly focus on enhancing treatment methods for spinal disorders, highlighted by their leading product, JAZZ®, which has been developed into an extensive range of solutions, particularly after their acquisition of Orthopaedic & Spine Development (OSD) in May 2021.
Innovative Solutions
IMPLANET has an extensive suite of products, providing a variety of solutions for orthopedic and spinal surgery. The JAZZ® system, in particular, stands out due to its advanced technology and has secured regulatory clearances from key health authorities, indicating a strong commitment to safety and efficacy in medical device manufacturing.
Partnerships and Growth
In 2022, IMPLANET forged a significant partnership with SANYOU MEDICAL, which is notable as China's second-largest medical device manufacturer. This collaboration aims to enhance IMPLANET's market reach and improve its service delivery in the ever-evolving landscape of medical technology. It holds great promise for expanding product availability and fostering innovation.
Financial Performance
With a dedicated workforce of 43 employees, IMPLANET reported consolidated revenue of €7.4 million, a testament to their focused strategy and operational efficiency. The company continues to thrive, establishing its presence within the Euronext Growth market.
Looking Ahead
As we anticipate the upcoming financial announcements, it is crucial for stakeholders to remain engaged and informed about IMPLANET’s performance and strategic developments. The financial calendar emphasizes the company's commitment to transparency and accountability in its operations.
Frequently Asked Questions
What is IMPLANET known for?
IMPLANET specializes in medical technology, particularly in manufacturing orthopedic implants and medical equipment.
When will IMPLANET release its 2024 Full-Year Results?
The results are scheduled to be released on March 4, 2025.
How can I stay updated on IMPLANET’s financial announcements?
It is advisable to follow IMPLANET's official communications and press releases for updates on their financial schedule.
What notable partnership has IMPLANET entered in recent years?
In 2022, IMPLANET partnered with SANYOU MEDICAL, enhancing their capabilities in the medical technology space.
Where is IMPLANET based?
IMPLANET is based near Bordeaux, France, and has a subsidiary located in Boston, USA.
